Save 60% Off all remaining inventory with Promo Code: ICE

‘Billion Dollar’ Epidiolex CBD Medication Presented To FDA For Approval

November 08, 2017

In a groundbreaking development, London-based GW Pharmaceuticals, just announced its brand new CBD drug application to the FDA…

The new drug, touted to be a billion-dollar cash cow for the company, integrates CBD for the “treatment of seizures associated with two specific types of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.”

Steve Schultz, a spokesperson from GW, said correctly that, “The submission is a significant event,” noting that the Epidiolex submission file contained thousands of documents, including preclinical and clinical information, as well as clinical data on 1,500 patients, 400 of whom have had more than a year of exposure to Epidiolex.

For their part, the FDA now has 60 days to either approve or fail the new medicine, with a view to having the product on the market by this time next year.

GW are hoping for big things form the new drug, due to what they say is “significant demand” from Lennox-Gastaut and Dravet patients populations.

Morgan Stanley analyst, Andrew S. Berens, wrote about the situation, “We expect focus will specifically be on anticipated drug-drug interaction (DDI) data expected at the meeting, as management anticipates presenting pooled data from the two Phase 3 LGS trials showing response rates at different thresholds and in the subgroups of patients with or without concomitant Onfi (clobazam).”

This raises some concerns about the connection between Clobazam and Epidiolex, but concerns that GW are not worried about in the slightest, “Our goal is to provide an additional option,” said the GW spokesperson, “We know that physicians and patients and parents of young patients desire to have a pharmaceutical medicine for the treatment of these seizures, especially these really challenging seizures.”

[Image credit- Pixabay]

The post ‘Billion Dollar’ Epidiolex CBD Medication Presented To FDA For Approval appeared first on Cannadelics.





Also in Education

Owning Guns is a Constitutional Right, Unless You’re a Cannabis User

September 28, 2022

Take two of the most hot-button, tendentious issues of our time – cannabis use and gun rights – combine them, and now we really have a debate. As the law currently stands, medical cannabis patients are not afforded their 2nd amendment right to bear arms. Technically, all cannabis consumers are banned from buying guns, but only medical […]

The post Owning Guns is a Constitutional Right, Unless You’re a Cannabis User appeared first on Cannadelics.

Continue Reading

Cannabis policy changes in Africa are welcome. But small producers are the losers

September 28, 2022

TESTSTSARDSAR

Cannabis policy changes in Africa are welcome. But small producers are the losers by Clemence Rusenga

Cannabis is a drug crop with a long history in Africa. Alongside coca and opium poppy, it has been subjected to international control for nearly a century. The International Opium Convention of 1925 institutionalised the international control system and extended the scope of control to cannabis. In 1961 a new international convention was adopted to […]

A link to your site, with your site's name and description as anchor text.

Continue Reading

University of Sydney to Offer Free Cannabis Testing

September 27, 2022

TESTSTSARDSAR

University of Sydney to Offer Free Cannabis Testing by Johnny Green

The University of Sydney is launching a fairly robust study in an attempt to, as the university describes it, “investigate cannabis consumption, behaviours, and attitudes among users.” Part of the study involves offering free, anonymous cannabis testing for people that cultivate their own cannabis in the Australian Capital Territory (ACT). Cannabis was decriminalized in 2020 in the […]

A link to your site, with your site's name and description as anchor text.

Continue Reading

Inventory Clearance Sale

Save 60% Off all remaining inventory with Promo Code: ICE